These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27517727)

  • 1. Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
    Bertuzzi F; Marazzi M; De Carlis LG; Rampoldi AG; Bonomo M; Antonioli B; Tosca MC; Galuzzi M; De Gasperi A; Colussi G
    Transplantation; 2016 Nov; 100(11):e117-e118. PubMed ID: 27517727
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
    Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide and rare adverse events.
    Cure P; Pileggi A; Alejandro R
    N Engl J Med; 2008 May; 358(18):1969-70; discussion 1971-2. PubMed ID: 18450614
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.
    Faradji RN; Tharavanij T; Messinger S; Froud T; Pileggi A; Monroy K; Mineo D; Baidal DA; Cure P; Ponte G; Mendez AJ; Selvaggi G; Ricordi C; Alejandro R
    Transplantation; 2008 Dec; 86(12):1658-65. PubMed ID: 19104401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exenatide convinces in a six-month study: HbA1c sunk significantly].
    MMW Fortschr Med; 2009 May; 151(19):51. PubMed ID: 19827448
    [No Abstract]   [Full Text] [Related]  

  • 6. [Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].
    MMW Fortschr Med; 2005 Aug; 147(31-32):55. PubMed ID: 16128203
    [No Abstract]   [Full Text] [Related]  

  • 7. G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.
    Zoso A; Serafini P; Lanzoni G; Peixoto E; Messinger S; Mantero A; Padilla-Téllez ND; Baidal DA; Alejandro R; Ricordi C; Inverardi L
    PLoS One; 2016; 11(6):e0157245. PubMed ID: 27285580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summaries for patients. Exenatide therapy for type 2 diabetes.
    Ann Intern Med; 2007 Apr; 146(7):I18. PubMed ID: 17404346
    [No Abstract]   [Full Text] [Related]  

  • 9. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?
    Ann Intern Med; 2005 Oct; 143(8):I30. PubMed ID: 16230718
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Islet transplantation for brittle type 1 diabetes: the UIC protocol.
    Gangemi A; Salehi P; Hatipoglu B; Martellotto J; Barbaro B; Kuechle JB; Qi M; Wang Y; Pallan P; Owens C; Bui J; West D; Kaplan B; Benedetti E; Oberholzer J
    Am J Transplant; 2008 Jun; 8(6):1250-61. PubMed ID: 18444920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blood sugar and pounds down, hardly hypoglycemias. New generation of antidiabetics ante portas].
    Einecke D
    MMW Fortschr Med; 2006 Aug; 148(35-36):4-6, 8, 10. PubMed ID: 16995353
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
    Rother KI; Spain LM; Wesley RA; Digon BJ; Baron A; Chen K; Nelson P; Dosch HM; Palmer JP; Brooks-Worrell B; Ring M; Harlan DM
    Diabetes Care; 2009 Dec; 32(12):2251-7. PubMed ID: 19808924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 15. [Exenatide trials for the treatment of type 2 diabetes].
    Fernández Landó L; Casellini CM
    Medicina (B Aires); 2009; 69(4):447-57. PubMed ID: 19770100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
    Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA(1c)) on exenatide treatment.
    Brooks AM; Lissett CA
    Diabet Med; 2009 Feb; 26(2):190. PubMed ID: 19236627
    [No Abstract]   [Full Text] [Related]  

  • 18. [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus].
    Perusicová J
    Vnitr Lek; 2008 Apr; 54(4):377-86. PubMed ID: 18630617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improved blood sugar control plus weight loss].
    Göke B
    MMW Fortschr Med; 2006 Aug; 148(33-34):51. PubMed ID: 16981389
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraportal islet allografts in type I diabetes mellitus.
    Alejandro R; Burke G; Shapiro ET; Strasser S; Nery J; Ricordi C; Esquenazi V; Miller J; Mintz DH
    Transplant Proc; 1992 Jun; 24(3):959-60. PubMed ID: 1604685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.